EX9 Stoklara Genel Bakış Bir onkoloji şirketi olan Exelixis Inc., Amerika Birleşik Devletleri'nde tedavisi zor kanserler için yeni ilaçların keşfedilmesi, geliştirilmesi ve ticarileştirilmesine odaklanmaktadır. Daha fazla detay
Ödüller Risk Analizi Tüm Risk Kontrollerini Gör Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Exelixis Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı US$32.86 52 Haftanın En Yüksek Seviyesi US$34.42 52 Haftanın En Düşük Seviyesi US$18.26 Beta 0.52 1 Aylık Değişim -2.75% 3 Aylık Değişim n/a 1 Yıllık Değişim 56.03% 3 Yıllık Değişim 93.81% 5 Yıllık Değişim 113.27% Halka arzdan bu yana değişim 69.38%
Son Haberler & Güncellemeler
Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors Nov 27
Independent Director recently sold €940k worth of stock Nov 07
Investor sentiment improves as stock rises 23% Nov 07 Exelixis, Inc. Reports Impairment of Long-Lived Assets for the Third Quarter Ended September 30, 2024
Exelixis, Inc. to Report Q3, 2024 Results on Oct 29, 2024 Oct 16 Exelixis, Inc Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine Daha fazla güncelleme görün
Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors Nov 27
Independent Director recently sold €940k worth of stock Nov 07
Investor sentiment improves as stock rises 23% Nov 07 Exelixis, Inc. Reports Impairment of Long-Lived Assets for the Third Quarter Ended September 30, 2024
Exelixis, Inc. to Report Q3, 2024 Results on Oct 29, 2024 Oct 16 Exelixis, Inc Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine
Independent Director recently sold €831k worth of stock Aug 14
Exelixis, Inc. Announces Initiation of Phase 1 Clinical Trial Evaluating XB010 in Patients with Advanced Solid Tumors Aug 08
Second quarter 2024 earnings released: EPS: US$0.78 (vs US$0.25 in 2Q 2023) Aug 07 Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $500 million worth of its shares.
Exelixis, Inc. Announces U.S. Food and Drug Administration Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors Aug 06
Exelixis, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 24
Independent Director recently sold €531k worth of stock May 24 Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA May 22
First quarter 2024 earnings released: EPS: US$0.12 (vs US$0.12 in 1Q 2023) May 01
Exelixis, Inc. Reaffirms Earnings Guidance for the Year 2024 May 01
Exelixis, Inc., Annual General Meeting, May 30, 2024 Apr 20
Exelixis, Inc. to Report Q1, 2024 Results on Apr 30, 2024 Apr 17
Executive Vice President of Commercial recently sold €932k worth of stock Mar 03
Full year 2023 earnings released: EPS: US$0.65 (vs US$0.57 in FY 2022) Feb 07
Exelixis, Inc. Provides Earnings Guidance for the for Fiscal Year 2024 Feb 07
Exelixis, Inc. Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024 Jan 25 Bristol Myers Squibb and Exelixis, Inc. Announce Four-Year Follow-Up Results from the CheckMate -9ER Trial Evaluating Opdivo (cabozantinib) Jan 24
Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $450 million worth of its shares. Jan 09 Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $450 million worth of its shares.
Exelixis Announces Initiation of the Stellar-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer Dec 04
Exelixis, Inc. Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023 Nov 11
Third quarter 2023 earnings released: EPS: US$0.003 (vs US$0.23 in 3Q 2022) Nov 02
Exelixis, Inc. Announces Detailed Results from Phase 3 Cabinet Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023 Oct 23
Exelixis, Inc. to Report Q3, 2023 Results on Nov 01, 2023 Oct 19
Exelixis, Inc. Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors Aug 25 Exelixis, Inc. Announces Vicki L. Goodman Concludes Her Service as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer
Exelixis, Inc. Provides Earnings Guidance for the Fiscal Year 2023 Aug 04
Exelixis, Inc. to Report Q2, 2023 Results on Aug 01, 2023 Jul 21
Exelixis, Inc. Elects Dave Johnson to its Board of Directors Jun 01
First quarter 2023 earnings released: EPS: US$0.12 (vs US$0.21 in 1Q 2022) May 10
Exelixis, Inc. Provides Earnings Guidance for the Fiscal Year 2023 May 10
Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors May 08 Bristol-Myers Squibb Company and Exelixis, Inc. Announces Opdivo in Combination with Cabometyx Shows Durable Survival with over Three Years of Follow-Up in the Checkmate -9Er Trial in First-Line Advanced Renal Cell Carcinoma Feb 15
Exelixis, Inc. and Sairopa B.V. Announces US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors Feb 14
Full year 2022 earnings released: EPS: US$0.57 (vs US$0.73 in FY 2021) Feb 08
Exelixis, Inc. Provides Revenue Guidance for Fiscal Year 2023 Feb 08
Exelixis, Inc. to Report Q4, 2022 Results on Feb 07, 2023 Jan 10
Exelixis, Inc. Provides Revenue Guidance for Full Year 2023 Jan 09 Exelixis, Inc. Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney Cancer Dec 23
Exelixis, Inc. Announces Board Appointments Dec 17
Exelixis, Inc. Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy Dec 10
Exelixis, Inc. Announces Initial Dose-Escalation Results from the First-In-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022 Dec 09
Insufficient new directors Nov 16
Third quarter 2022 earnings released: EPS: US$0.23 (vs US$0.12 in 3Q 2021) Nov 03
Exelixis, Inc. Provides Revenue Guidance for 2022 Nov 02
Exelixis, Inc. Announces Promising Initial Dose-Escalation Results from the First-In-Human Phase 1 JEWEL-101 Trial Evaluating XB002 in Patients with Advanced Solid Tumors at ENA 2022 Oct 27
Exelixis, Inc. to Report Q3, 2022 Results on Nov 01, 2022 Oct 19
Exelixis, Inc. Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ESMO 2022 Sep 11
Exelixis, Inc. Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer at ESMO 2022 Sep 08
Second quarter 2022 earnings released: EPS: US$0.22 (vs US$0.31 in 2Q 2021) Aug 11
Exelixis, Inc. Maintains Earnings Guidance for the Fiscal Year 2022 Aug 10
Exelixis, Inc. to Report Q2, 2022 Results on Aug 09, 2022 Jul 28
Exelixis, Inc. Announces COSMIC-313 Met Its Primary Endpoint Jul 12
Investor sentiment improved over the past week Jun 25
Exelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal Cancer Jun 22
Executive Vice President of Commercial recently sold €320k worth of stock Jun 04
Exelixis, Inc. Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients May 27
Exelixis, Inc. Provides Earnings Guidance for the Fiscal Year 2022 May 12
First quarter 2022 earnings released: EPS: US$0.21 (vs US$0.005 in 1Q 2021) May 11
Insufficient new directors Apr 27 Exelixis, Inc. Announces Initiation of First-In-Human Phase 1 Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgkin’s Lymphoma
Exelixis, Inc. Announces Charles Cohen to Retire from Board of Directors Apr 14
Co-Founder & Independent Chairman recently sold €1.5m worth of stock Mar 02
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 18
Exelixis, Inc. Provides Earnings Guidance for the Year 2022 Feb 18
Bristol Myers Squibb and Exelixis, Inc. Announces Two-Year Follow-Up Results from Analyses of the Phase 3 CheckMate -9ER Trial Feb 15
Exelixis, Inc. Provides Sales Guidance for the Year 2022 Feb 11
Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapies in Patients with Advanced Colorectal Cancer at ASCO GI 2022 Jan 19
Exelixis, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2021; Revenue Guidance for the Full Year 2022 Jan 10
Exelixis, Inc. Announces Enrollment Completion in Phase 3 CONTACT-03 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Renal Cell Carcinoma Jan 07
Exelixis, Inc. Announces Initiation of Phase 1B Trial Evaluating XL092 in Combination with Immuno-Oncology Therapies in Patients with Advanced Solid Tumors Dec 16
Executive Vice President of Commercial recently sold €266k worth of stock Nov 30
Third quarter 2021 earnings released: EPS US$0.12 (vs US$0.10 loss in 3Q 2020) Nov 04
Exelixis Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX® in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ESMO 2021 Sep 21 Hissedar Getirileri EX9 DE Biotechs DE Pazar 7D 0.5% 3.1% 0.5% 1Y 56.0% -13.8% 7.2%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: EX9 geçen yıl % -13.8 oranında getiri sağlayan German Biotechs sektörünü aştı.
Getiri vs Piyasa: EX9 geçen yıl % 7.2 oranında getiri sağlayan German Piyasasını aştı.
Fiyat Oynaklığı Is EX9's price volatile compared to industry and market? EX9 volatility EX9 Average Weekly Movement n/a Biotechs Industry Average Movement 7.0% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.7% 10% least volatile stocks in DE Market 2.4%
İstikrarlı Hisse Senedi Fiyatı: EX9 hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.
Zaman İçindeki Volatilite: EX9 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri .
Şirket Hakkında Bir onkoloji şirketi olan Exelixis, Inc, Amerika Birleşik Devletleri'nde tedavisi zor kanserler için yeni ilaçların keşfi, geliştirilmesi ve ticarileştirilmesine odaklanmaktadır. Şirket, önceden anti-anjiyojenik tedavi almış ileri evre renal hücreli karsinom hastalarının tedavisi için CABOMETYX tabletleri ve progresif ve metastatik medüller tiroid kanserinin tedavisi için COMETRIQ kapsülleri sunmaktadır. CABOMETYX ve COMETRIQ, MET, AXL, RET ve VEGF reseptörleri dahil olmak üzere çoklu tirozin kinazların inhibitörü olan cabozantinib'den türetilmiştir.
Daha fazla göster Exelixis, Inc. Temel Bilgiler Özeti Exelixis'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? EX9 temel i̇stati̇sti̇kler Piyasa değeri €9.26b Kazançlar(TTM ) €447.83m Gelir(TTM ) €2.00b
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) EX9 gelir tablosu (TTM ) Gelir US$2.08b Gelir Maliyeti US$78.00m Brüt Kâr US$2.00b Diğer Giderler US$1.54b Kazançlar US$466.92m
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2024/12/29 10:29 Gün Sonu Hisse Fiyatı 2024/12/27 00:00 Kazançlar 2024/09/30 Yıllık Kazançlar 2023/12/31
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.
Analist Kaynakları Exelixis, Inc. 40 Bu analistlerden 21, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum Ishan Majumdar Baptista Research Peter Lawson Barclays Etzer Darout BMO Capital Markets Equity Research
Göster 37 daha fazla analist 
